This non-reliance filing is a severe negative signal for a $2M market cap company — expect significant selling pressure and potential Nasdaq listing qualification issues. Monitor for shareholder lawsuits and the forthcoming 10-K restatement for actual dollar impacts.
Price Chart
Executive Summary
INVO Fertility filed an 8-K announcing that its previously issued unaudited financial statements for Q1, Q2, and Q3 2025 can no longer be relied upon due to multiple accounting errors related to preferred stock classification, derivative accounting, debt extinguishment, and warrant liability classification. The restatement is limited to balance sheet and equity line items and does not affect revenue or operating loss, but the non-reliance filing is a severe credibility event for a micro-cap company with a $2M market cap.
Key Facts
- Audit committee concluded on June 1, 2026 that Q1, Q2, and Q3 2025 unaudited financials should no longer be relied upon
- Errors include: incorrect classification of Series C-1 and C-2 preferred stock, improper treatment of convertible debenture with embedded derivative, incorrect gain on settlement recognition, wrong equity classification of warrants, and improper debt extinguishment accounting
- Restatement does not impact revenue or loss from operations — limited to assets, liabilities, equity, other income/expense, and net income/loss
- Company intends to present restated figures in the forthcoming 2025 10-K rather than amending prior 10-Qs
- Market cap is approximately $2M, making this a material credibility event for a micro-cap issuer
Financial Impact
Dollar amounts of the errors are not disclosed in the filing. The restatement affects balance sheet classification and non-operating line items across three quarters of 2025.
Risk Factors
- Shareholder class action lawsuits are nearly guaranteed following a non-reliance restatement
- Potential Nasdaq continued listing deficiency if filing delays or credibility issues arise
- Further dilution risk if the company needs to raise capital to address any restatement-related liabilities or litigation costs
- Management credibility severely damaged — future financing likely to be more expensive or unavailable
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-026772 |
| Document: 0001493152-26-026772-index-headers.html | 0001493152-26-026772 |
| Document: 0001493152-26-026772-index.html | 0001493152-26-026772 |
| Document: 0001493152-26-026772.txt | 0001493152-26-026772 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 9, 2026 17d ago | SC 13G/A | $0.7275 $0.5576 | ▲ +23.35% | ▲ +21.39% | $0.5869 (+19.33%) |
Aug 28, 2026 8w ago | 8-K | $1.00 $0.9850 | ▲ +1.50% | ▲ +1.61% | $0.5869 (+41.31%) |
Aug 17, 2026 10w ago | 8-K | $1.53 $1.03 | ▼ −32.68% | ▼ −31.49% | $0.5869 (−61.64%) |
Aug 17, 2026 10w ago | Press Release | $1.53 $1.03 | ▲ +32.68% | ▲ +31.49% | $0.5869 (+61.64%) |
Aug 5, 2026 11w ago | EFFECT | $1.08 $1.01 | ▲ +6.05% | ▲ +6.40% | $0.5869 (+45.40%) |
Jun 25, 2026 17w ago | 8-K | $2.45 $1.62 | ▼ −33.88% | ▼ −36.04% | $0.5869 (−76.04%) |
Jun 22, 2026 18w ago | Press Release | $1.39 $2.45 | ▼ −76.26% | ▼ −78.33% | $0.5869 (+57.78%) |
Jun 16, 2026 18w ago | 8-K | $1.59 $1.32 | ▼ −16.98% | ▼ −15.94% | $0.5869 (−63.09%) |
Jun 2, 2026 20w ago | Press Release | $1.70 $1.41 | ▲ +17.06% | ▲ +13.24% | $0.5869 (+65.48%) |
Jun 2, 2026 21w ago | 8-K | $1.52 $1.40 | ▼ −7.89% | ▼ −4.93% | $0.5869 (−61.39%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers